Trials
4 active
10 in total · 3 in the EU
What this is
- How it works
- A short strand of RNA that switches off one gene, so the body makes less of one protein.Lp(a) small interfering RNA (siRNA)
- Tested for
- Cardiovascular Disease (2 trials), Atherosclerotic Cardiovascular Disease
- Main trialPhase 3
- “The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).”In the company’s words, NCT05581303 on ClinicalTrials.gov
- Other names
- AMG 890 · ARO-LPA
Other drugs for Cardiovascular Disease
- MezigdomideCelgene · Phase 3
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- ObicetrapibNewAmsterdam Pharma · Phase 3
- MilvexianJohnson & Johnson (Janssen) · Bristol Myers Squibb · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- VicagrelJiangsu vcare pharmaceutical technology co., LTD · Phase 3
Coming up3
- 31 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- 15 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 20 Oct 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Mar 2028 | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | |
| Phase 3Recruiting | 15 Jun 2028 | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial | |
| Phase 3Recruiting | 20 Oct 2031 | OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events | |
| Phase 2Completed | 27 Dec 2021 | Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study | |
| Phase 1Completed | 12 Nov 2021 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a) | |
| Phase 1Completed | 5 Apr 2023 | A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment | |
| Phase 1Completed | 18 Apr 2023 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a) | |
| Phase 1Completed | 24 Oct 2023 | A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment | |
| Phase 1Completed | 29 Nov 2024 | A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants | |
| Phase 3Authorised | not given | A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026